{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:40:50Z","timestamp":1792593650378,"version":"4.5.0"},"reference-count":26,"publisher":"Pan African Medical Journal","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pan Afr Med J"],"abstract":"<jats:p>Introduction: in the Antibody-Mediated Prevention (AMP) trials, a broadly neutralizing antibody called VRC01 was infused intravenously every two months to test its safety and HIV prevention efficacy. The AMP trial conducted in sub-Saharan Africa, called HVTN 703, enrolled women without HIV who were not pregnant or breastfeeding but who were behaviorally vulnerable to HIV-1 infection. We conducted a qualitative study in Malawi to explore the motivations and experiences of trial participants.\n\n \n\nMethods: between September and December 2018, we purposively selected and interviewed 12 out of 100 women enrolled in the AMP trial at the UNC Project site in Lilongwe, Malawi. We conducted in-depth interviews (IDI) with women who were retained in the trial. All IDIs were conducted in Chichewa, digitally recorded, and then transcribed into English. Data was analyzed using thematic analysis.\n\n \n\nResults: women participated in the AMP trial due to a range of perceived benefits. The primary reason was access to better quality medical care, accompanied by financial benefits and altruism. Participants' research experiences and their continued participation in the AMP trial were influenced by the research clinic environment and the nature of their interactions with research staff. Regardless of pre-existing study expectations, feeling welcomed and being able to openly interact with the study staff encouraged them to continue participating in the study.\n\n \n\nConclusion: antibody-mediated prevention study participants enrolled and continued their participation because of perceived benefits such as access to quality health care, finances, and altruism. Provision of other health services to research participants promotes participation in the trials.<\/jats:p>","DOI":"10.11604\/pamj.2026.54.16.52074","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:58:40Z","timestamp":1792591120000},"source":"Crossref","is-referenced-by-count":0,"title":["Reasons for participation and experiences of women in an antibody-mediated HIV prevention clinical trial in Malawi"],"prefix":"10.11604","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-9382-2069","authenticated-orcid":false,"given":"Ruth Naomi","family":"Holla","sequence":"first","affiliation":[{"name":"World Health Organization, Lilongwe, Malawi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agatha","family":"Bula","sequence":"additional","affiliation":[{"name":"UNC Project, Lilongwe, Malawi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adamson","family":"Muula","sequence":"additional","affiliation":[{"name":"Kamuzu University of Health Sciences, Chichiri, Blantyre 3, Malawi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Hosseinipour","sequence":"additional","affiliation":[{"name":"UNC Project, Lilongwe, Malawi"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4870","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"ref0","unstructured":"The Joint United Nations Programme on HIV and AIDS (UNAIDS). HIV prevention. Accessed 8th May, 2021."},{"key":"ref1","unstructured":"Ministry of Health, Malawi. Malawi Population-Based HIV Impact Assessment (MPHIA) 2015-2016: Final Report. 2018."},{"key":"ref2","unstructured":"National Statistical Office (NSO) (Malawi), ICF. Malawi Demographic and Health Survey 2015-2016. 2017. Accessed 9th March, 2026."},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Kharsany AB, Karim QA. HIV Infection and AIDS in Sub-Saharan Africa: Current Status, Challenges and Opportunities. Open AIDS J. 2016 Apr 8;10:34-48. PubMed | Google Scholar","DOI":"10.2174\/1874613601610010034"},{"key":"ref4","unstructured":"Khan P. AIDS Vaccine Handbook: Global Perspectives. 2005. Accessed 9th March, 2026."},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Kost RG, Lee LM, Yessis J, Coller BS, Henderson DK; Research Participant Perception Survey Focus Group Subcommittee. Assessing research participants' perceptions of their clinical research experiences. Clin Transl Sci. 2011 Dec;4(6):403-13. PubMed | Google Scholar","DOI":"10.1111\/j.1752-8062.2011.00349.x"},{"key":"ref6","unstructured":"HIV Vaccine Trials Network. Accessed 12th May, 2021."},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Corey L, Gilbert PB, Juraska M, Montefiori DC, Morris L, Karuna ST et al. Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. N Engl J Med. 2021 Mar 18;384(11):1003-1014. PubMed | Google Scholar","DOI":"10.1056\/NEJMoa2031738"},{"key":"ref8","unstructured":"The HIV Prevention Trials Network (HVTN). HVTN 703\/HPTN 081. Accessed 8th May, 2021."},{"key":"ref9","unstructured":"Centers for Disease Cotrol (CDC). Large Clinical Trial of Broadly Neutralizing, HIV Prevention Antibodies Launched. 2019. Accessed 8th May, 2021."},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Stadler JJ, Delany S, Mntambo M. Women\u00b4s perceptions and experiences of HIV prevention trials in Soweto, South Africa. Soc Sci Med. 2008 Jan;66(1):189-200. PubMed | Google Scholar","DOI":"10.1016\/j.socscimed.2007.08.021"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Mfutso-Bengo J, Ndebele P, Jumbe V, Mkunthi M, Masiye F, Molyneux S et al. Why do individuals agree to enroll in clinical trials? A qualitative study of health research participation in Blantyre, Malawi. Malawi Med J. 2008 Jun;20(2):37-41. PubMed | Google Scholar","DOI":"10.4314\/mmj.v20i2.10898"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Mfutso-Bengo J, Manda-Taylor L, Masiye F. Motivational factors for participation in biomedical research: evidence from a qualitative study of biomedical research participation in Blantyre District, Malawi. J Empir Res Hum Res Ethics. 2015 Feb;10(1):59-64. PubMed | Google Scholar","DOI":"10.1177\/1556264614559888"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Maguire M, Delahunt B. Doing a thematic analysis: A practical, step-by-step guide for learning and teaching scholars. Irel J High Educ. 2017;9(3). Google Scholar","DOI":"10.62707\/aishej.v9i3.335"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Nappo SA, Iafrate GB, Sanchez ZM. Motives for participating in a clinical research trial: a pilot study in Brazil. BMC Public Health. 2013 Jan 10;13:19. PubMed | Google Scholar","DOI":"10.1186\/1471-2458-13-19"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Stunkel L, Grady C. More than the money: a review of the literature examining healthy volunteer motivations. Contemp Clin Trials. 2011 May;32(3):342-52. PubMed | Google Scholar","DOI":"10.1016\/j.cct.2010.12.003"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Nyaoke BA, Mutua GN, Sajabi R, Nyasani D, Mureithi MW, Anzala OA. Volunteer motivators for participating in HIV vaccine clinical trials in Nairobi, Kenya. PLoS One. 2017 Sep 7;12(9):e0183788. PubMed | Google Scholar","DOI":"10.1371\/journal.pone.0183788"},{"key":"ref17","unstructured":"National Institute for Health Research (NIHR). Record number of patients take part in clinical research University of Leeds. 2019. Accessed 8th May, 2021."},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Abiiro GA, Mbera GB, De Allegri M. Gaps in universal health coverage in Malawi: a qualitative study in rural communities. BMC Health Serv Res. 2014 May 22;14:234. PubMed | Google Scholar","DOI":"10.1186\/1472-6963-14-234"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Feldblum PJ, Adeiga A, Bakare R, Wevill S, Lendvay A, Obadaki F et al. SAVVY Vaginal Gel (C31G) for Prevention of HIV Infection: A Randomized Controlled Trial in Nigeria. PLoS One. 2008 Jan 23;3(1):e1474. PubMed | Google Scholar","DOI":"10.1371\/journal.pone.0001474"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Peterson L, Nanda K, Opoku BK, Ampofo WK, Owusu-Amoako M, Boakye AY et al. SAVVY\u00ae (C31G) Gel for Prevention of HIV infection in Women: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial in Ghana. PLoS One. 2007 Dec 19;2(12):e1312. PubMed | Google Scholar","DOI":"10.1371\/journal.pone.0001312"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Peterson L, Taylor D, Roddy R, Belai G, Phillips P, Nanda K et al. Tenofovir Disoproxil Fumarate for Prevention of HIV Infection in Women: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Trial. PLoS Clin Trials. 2007 May 25;2(5):e27. PubMed | Google Scholar","DOI":"10.1371\/journal.pctr.0020027"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Gordon SB, Chinula L, Chilima B, Mwapasa V, Dadabhai S, Mlombe Y; Malawi Research Ethics Workshop 2018 Participants. A Malawi guideline for research study participant remuneration. Wellcome Open Res. 2018 Dec 19;3:141. PubMed | Google Scholar","DOI":"10.12688\/wellcomeopenres.14668.1"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"DiClemente RJ, Ruiz MS, Sales JM. Barriers to Adolescents\u00b4 Participation in HIV Biomedical Prevention Research. J Acquir Immune Defic Syndr. 2010 Jul;54 Suppl 1(Suppl 1):S12-7. PubMed | Google Scholar","DOI":"10.1097\/QAI.0b013e3181e1e2c0"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Buchbinder SP, Metch B, Holte SE, Scheer S, Coletti A, Vittinghoff E. Determinants of Enrollment in a Preventive HIV Vaccine Trial: Hypothetical Versus Actual Willingness and Barriers to Participation. J Acquir Immune Defic Syndr. 2004 May 1;36(1):604-12. PubMed | Google Scholar","DOI":"10.1097\/00126334-200405010-00009"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Perry HB, Zulliger R, Rogers MM. Community Health Workers in Low-, Middle-, and High-Income Countries: An Overview of Their History, Recent Evolution, and Current Effectiveness. Annu Rev Public Health. 2014;35:399-421. PubMed | Google Scholar","DOI":"10.1146\/annurev-publhealth-032013-182354"}],"container-title":["Pan African Medical Journal"],"original-title":[],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:58:46Z","timestamp":1792591126000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.panafrican-med-journal.com\/content\/article\/54\/16\/full\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":26,"URL":"https:\/\/doi.org\/10.11604\/pamj.2026.54.16.52074","relation":{},"ISSN":["1937-8688"],"issn-type":[{"value":"1937-8688","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"article-number":"52074"}}